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Abstract: Fluctuations of motor symptoms make clinical assessment in Parkinson’s disease a 
complex task. New technologies aim to quantify motor symptoms, and their remote application 
holds potential for a closer monitoring of treatment effects. The focus of this study was to explore 
the potential of a stepping in place task using RGB-Depth (RGBD) camera technology to assess 
motor symptoms of people with Parkinson’s disease. In total, 25 persons performed a 40 s stepping 
in place task in front of a single RGBD camera (Kinect for Xbox One) in up to two different 
therapeutic states. Eight kinematic parameters were derived from knee movements to describe 
features of hypokinesia, asymmetry, and arrhythmicity of stepping. To explore their potential 
clinical utility, these parameters were analyzed for their Spearman’s Rho rank correlation to clinical 
ratings, and for intraindividual changes between treatment conditions using standard response 
mean and paired t-test. Test performance not only differed between ON and OFF treatment 
conditions, but showed moderate correlations to clinical ratings, specifically ratings of postural 
instability (pull test). Furthermore, the test elicited freezing in some subjects. Results suggest that 
this single standardized motor task is a promising candidate to assess an array of relevant motor 
symptoms of Parkinson’s disease. The simple technical test setup would allow future use by patients 
themselves. 
Keywords: RGBD camera; movement analysis; Parkinson’s disease; postural instability 
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1. Introduction 
Parkinson’s disease is a progressive neurodegenerative disease with peak of onset in the sixth 
decade of life. The brain structures and functions affected result in a movement disorder defined by 
specific motor dysfunctions [1]. Patients with Parkinson’s disease (PWPD) may suffer from different 
combinations of slowing and shortness of movement (bradykinesia), increased muscle tone (rigidity), 
tremor, and typical postural instability [1]. This results in a hypokinetic gait disturbance, which may 
also include freezing of gait (FOG), characterized by episodic hesitations of stepping, or inefficient 
stepping with high frequency (festination), resulting in episodic arrest of locomotor behavior [2–4]. 
FOG may be triggered by various factors, has been related to increased risk of falling, and is a 
hallmark of transition into advanced disease stages [2,5]. 
Today, several treatment options are available to relieve the symptoms of this disorder, and their 
appropriate dosing depends on close observation of motor signs [6]. Thus, the recognition of these 
motor signs is not only critical for the diagnosis of Parkinson’s disease (PD), but also forms the basis 
of treatment decisions in PWPD [7]. Several instruments are clinically used for this purpose: a 
standardized clinical rating scale, such as the ‘Movement Disorder Society—Unified Parkinson’s 
disease rating scale (MDS-UPDRS) [7] and the Hoehn and Yahr scale [8], or patient self-reported 
outcomes [9]. A general limitation when assessing PD motor symptoms in a clinical setting is their 
fluctuating nature. As a well-known and bothersome complication of long-term medication in 
PWPD, the presence and severity of symptoms may considerably change in the short-term, e.g., in 
relation to medication intake, which may span from rather unimpaired, in medication ON state, to 
immobile, when drug effects wear off (medication OFF). Furthermore, additional motor features, 
such as dyskinesia, may indicate adverse effects of PD treatment [10]. Single point clinical 
assessments are not able to capture such fluctuations, and clinical rating scales may have limited 
sensitivity to quantify small-range changes in motor symptoms. 
A manifold of technologies is available for a potentially more sensitive and rater-independent 
quantification of motor functions [11], which previous reviews explored for their application in PD 
[12–15]. For the assessment of motor fluctuations in PWPD, two approaches have been proposed: (1) 
non-standardized assessment, i.e., continuous tracking during everyday activities, which requires 
wearable sensors [16,17]; and (2) multi-point assessment of relevant motor symptoms in standard 
motor tasks, which requires technologies that are easily applicable by patients themselves. In this 
study, we follow the second approach, using 3D full body motion capture by RGB-Depth (RGBD) 
consumer cameras. The technology has already been applied for movement analysis in the clinical 
context, e.g., to analyze postural control and gait in different neurological disorders (e.g., PD [18], 
multiple sclerosis [19], and ataxia [20]), and showed good agreement with marker-based motion 
analysis standards [21]. The analyses presented here are based on observations from lab-based 
assessments, but the simple application of this technology would allow future application as patient-
based assessment. 
The stepping in place task (SIP), where patients are asked to repetitively walk on a spot while 
suppressing forward locomotion, was used here, based on prior evidence and low requirement of 
recording space. The task is long known as a clinical test for vestibular dysfunction when performed 
with eyes closed [22], but may also test components of gait and postural control when performed 
with eyes open [23]. SIP was used by Nantel et al. [24] to analyze temporal parameters, such as 
cadence, time symmetry, and arrhythmicity, in PWPD with and without FOG, contrasting their 
performance to a group of healthy subjects. They were the first to report that SIP triggered a freezing 
of stepping movements in patients with FOG, which was later confirmed by Dijsseldonk et al. [25]. 
Based on these findings, an array of relevant PD-specific motor symptoms may potentially be 
assessed in stepping in place behavior. 
Our study is the first to utilize RGBD technology to derive kinematic parameters from SIP, and 
our spatial analysis of stepping behavior extends previous descriptions of SIP performance in PWPD. 
The objective was to quantitatively describe PWPDs’ performance of an SIP motor assessment using 
data from a single RGBD camera. For this purpose, algorithms for kinematic parameter extraction 
were developed and outcomes were analyzed regarding their potential for clinical use. According to 
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previous experience and published evidence, we expected the test to be feasible for most patients 
with PD, but might be experienced as challenging for those in higher disease stages. We further 
expected a relation between test performance and disease severity, which would be expressed in 
correlations of kinematic parameters to clinical ratings of disease severity, as well as parameter 
differences between recordings taken in OFF and ON conditions. 
2. Materials and Methods 
2.1. Subjects and Clinical Testing 
In total, data from 25 PWPD were used in this work (see Table 1), originating from two studies 
performed at an academic medical center (Charité—Universitätsmedizin Berlin, Germany, IRB 
approval EA1/012/17 and EA1/216/15). The studies explored motor outcomes from an RGBD sensor 
as a secondary aim while measuring patients in different therapeutic states defined as ON 
(depending on study defined as either optimized deep brain stimulation (DBS) or optimized 
symptomatic medication) or OFF (defined as either standardized withdrawal of DBS or medication). 
Inclusion criteria for the two studies were the clinical diagnosis of PD, according to UK Brain Bank 
Criteria [26]. Patients with limitations in motor performance unrelated to PD, including major 
psychiatric or cognitive disturbance, were excluded. For the purpose of this analysis, we additionally 
excluded recordings with dyskinesia reported at the time of assessment. All participants gave written 
informed consent for the assessment, analysis, and scientific publication of findings. Study data can 
be made available only on reasonable request. 
The dataset comprised 20 assessments in ON and 13 assessments in OFF (including 10 
intraindividual data pairs of ON and OFF assessments). The sample size requirements were based 
on recommendations from [14] for technical feasibility studies, which suggests first trials in up to 10 
participants. Each assessment consisted of the performance of the full MDS-UPDRS III, as well as one 
recording of the stepping in place task. From the MDS-UPDRS III, the total score (range 0–142) and 
ratings for freezing of gait (item 11, range 0–4) and pull test (item 12, range 0–4) were available for 
analysis. 
Table 1. Description of subgroups, where metrical measures are given as mean and standard 
deviation and ordinal data as number of reached scores for each value. 
 ALL ON OFF ON-OFF 
N subjects 25 20 13 10 
male 18 15 8 6 
female 7 5 5 4 
Age (years) 65.3 (±9.4) 65.5 (±11.05) 66.2 (±8.0) 65.3 (±8.7) 
Weight (kg) 75.0 (±13.5) 74.1 (±13.5) 76.3 (±12.5) 76.2 (±13.8) 
Height (cm) 168.4 (±6.8) 167.7 (±6.1) 170.4 (±7.8) 168.4 (±5.3) 
Disease Duration (years) 12.8 (±8.1) 12.1 (±8.0) 11.6 (±6.6) 10.1 (±7.2) 
MDS-UPDRS-III 28.3 (±14.7) 25.3 (±13.7) 34.9 (±15.1) 
ON: 28.8 (±13.4) 
OFF: 37.2 (±14.5) 
N-item 11 (FOG) 23/4/6/0/0 14/3/3/0/0 9/1/3/0/0 ON: 8/2/0/0/0 
0/1/2/3/4 OFF: 7/3/0/0/0 
N-item 12 (Pull test) 12/10/6/1/1 8/4/5/2/0 4/6/1/1/1 ON: 4/3/2/1/0 0/1/2/3/4 OFF: 1/6/1/1/1 
2.2. Stepping in Place 
The study protocol of both studies included a standardized instruction of SIP to induce 
performance in self-selected, comfortable pace. To avoid exhaustion after performance, the SIP was 
limited to 40 s recording length, starting from onset of performance to automated stop of recording. 
Participants were explicitly told to avoid forward movement, but received no further instructions on 
Sensors 2020, 20, 5465 4 of 13 
 
leg or arm movements, nor prior demonstration of the task. A short testing performance of the task 
was explicitly allowed. If participants moved further than 1 m forward, the task was repeated, while 
reminding them to remain on spot and avoid moving forward. The tests were performed in common 
street clothing and usual footwear, excluding heeled shoes. Very loose clothing was asked to be taken 
off. 
2.3. Technical Setup 
Instrumental recording of SIP used a marker-free motion capture technology based on a 
consumer RGBD camera (Microsoft Kinect for Xbox One). The Kinect camera was accessed by the 
official Microsoft Kinect SDK (Version 14.09) at a framerate of 30 Hz, using software developed for 
that purpose (Motognosis Labs V1.2, Motognosis GmbH, Berlin, Germany). The camera was placed 
on a movable trolley at 1.4 m height with a vertical angle of −9° (see Figure 1). Since the area of highest 
depth resolution is between 1.5 and 3.5 m, participants were placed facing the camera at a 2.5 m 
distance. 
 
Figure 1. Technical setup of the motion capture system. Kinect camera was attached at 1.4 m height 
on a movable trolley with a pitch angle of roughly −9° while participants stood at a 2.5 m distance. 
The Microsoft Kinect SDK provided depth point clouds of the person in the measurement area, 
and identified 25 artificial anatomical landmarks (see Figure 2) representing the location of body parts 
and major joints (e.g., knees, ankles, hands, head), which were recorded and exported as .csv files. 
2.4. Data Processing and Calculation of Kinematic Parameters 
Since the anatomical landmarks of the feet and ankles tend to show noisy behavior during SIP 
according to prior technical validation [21], 3D knee movements were used to detect stepping 
behavior and to derive a parameter set for use in PWPD. Stepping movements were split in stance 
and step phases, similar to the stance and swing phase of each leg in a gait cycle during normal 
walking (see Figure 3). 
Data pre-processing comprised the following steps: 
1. To compensate for the subject’s position changes in the measurement area, we used the 3D 
positions of each knee as time series in relative position to the relating hip position. This eliminates 
possible errors due to the tendency to move towards the sensor. 
2. A median filter (window size 5 frames) was applied to smoothen the anterior–posterior knee 
movement signal and reduce noise. 
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3. All minima of the filtered signal were detected and interpolated linearly, creating a minima-
signal to provide a base level of minor landmark shifts over time caused by changes in the detected 
3D user mask. 
4. The minima-signal was subtracted from the anterior–posterior knee movement signal to 
eliminate smaller measurement errors when the knees were straight. 
5. A threshold of 2.5 cm for anterior–posterior knee amplitude was defined as suitable to 
differentiate between step (>2.5 cm) and stance (<2.5 cm) phase. The threshold was identified by 
visual inspection of recordings. 
 
Figure 2. Recorded depth data of a masked participant (left) with 25 artificial anatomical landmarks 
(right) provided by the Kinect SDK. 
 
Figure 3. Representation of anterior–posterior movements of the right (thick black line) and left (thin 
dotted line) knee. The dashed box shows a complete stepping cycle including one step of each side. 
The following two phases are differentiated: Step phase of the right leg (from point 1 to 3) and stance 
phase (from point 3 to 4). Point 2 indicates the moment of anterior knee excursion (maximum hip 
flexion) and is used for the calculation of the knee amplitudes. 
From the detected step and stance phases, we derived eight kinematic parameters to describe 
major motor features of PD (Table 2). All parameters, besides cadence and asymmetry, were 
calculated separately for each body side, and then combined as their mean for further analysis. 
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Table 2. Description of eight kinematic parameters from VPC recordings of stepping in place (SIP) 
task performance. 
Parameter Name Unit Description 
Cadence Steps/min Steps per minute 
Knee Amplitude cm Anterior–posterior range of motion of knees 
Asymmetry % Logarithmic ratio between knee amplitudes of larger side to smaller side 
Average Step Time s Average time required for a step during the measurement 
Longest Step Time s Maximal time required for a step during the measurement 
Arrhythmicity % Ratio between standard deviation and average of the step time 
Average Stance Time s Average time between step movements 
Longest Stance Time s Maximal time between step movements 
Equations for the calculation of arrhythmicity (step time coefficient of variation) (1) and 
asymmetry (2) were taken from common definitions, as, for example, provided by Plotnik et al. [27]. Arrhythmicity =  100 ∗ std StepTimesmean StepTimes  (1) 
Asymmetry =  100 ∗  mean(AmplitudesAmplitudesmean(Amplitudes )  (2) 
Since asymmetry is expressed as ratio between both sides, persons with small knee amplitudes 
show higher asymmetry measures for similar absolute amplitude differences. 
2.5. Statistical Analysis 
Descriptive statistics are given for metric kinematic parameters as mean and standard deviation. 
To explore confounding effects of age, height, and weight on SIP parameters, Pearson’s correlations 
were performed in the ON subgroup. 
Relation to disease severity was explored by correlating pooled recordings with the 
corresponding MDS-UPDRS III total score and pull test score, using Spearman’s rank correlation. 
Pooled data is here used to provide higher heterogeneity in clinical symptom severity. From the 
subgroup of 10 patients with paired data from recordings in ON and OFF available, within-group 
comparisons were calculated between ON and OFF therapeutic states, reported as absolute and 
relative differences (percentage change from value in OFF condition), along with statistics from 
paired t-tests. Additionally, the standardized response mean (SRM) was provided as ratio of average 
difference and standard deviation of differences between OFF and ON. Due to the exploratory nature 
and small cohort size, analyses were not corrected for multiple comparisons, and the significance 
levels for all tests were set at 1%. 
All statistics were calculated using Python 3.5 and the SciPy package version 0.18.1. Diagrams 
were created with Seaborn (package version 0.7.1) and Matplotlib (package version 2.0.0). 
3. Results 
3.1. Descriptive Statistics and Analysis of Potential Confounding Effects 
The descriptive statistics of all eight derived kinematic parameters are provided for the pooled 
dataset, as well as the subsets of recordings acquired in ON and OFF (Table 3). In the subset of ON 
recordings, i.e., in a state of least expression of PD motor symptoms, the correlations between 
kinematic parameters and age, height, or body weight did not indicate relevant confounding effects 
by overall non-significant and small correlation coefficients (|r| < 0.27 for age, <0.15 for height and 
<0.36 for weight). 
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Table 3. Descriptive statistics for SIP parameters on the left for the whole sample and subset of 
recordings in ON and OFF treatments states, and on the right, estimation of confounding effects of 
age, height, and weight in the subset of recordings in ON. 
 Descriptive Statistics Confounder Analysis in ON (n = 20) 
 Mean (SD) Pearson’s Correlation Coefficient r (p-Value) 
 ALL (n = 33) ON (n = 20) OFF (n = 13) Age Height Weight 
Cadence (steps/min) 97.6 (27.3) 96.6 (27.1) 99.2 (28.6) −0.271 (0.247) 0.132 (0.682) −0.358 (0.253) 
Knee Amplitude (cm) 12.5 (7.4) 13.9 (5.5) 10.2 (9.3) 0.228 (0.334) 0.151 (0.640) 0.280 (0.378) 
Asymmetry (%) 18.2 (19.9) 15.6 (14.1) 22.1 (26.8) −0.133 (0.577) 0.066 (0.839) −0.173 (0.591) 
Average Step Time (s) 0.72 (0.21) 0.77 (0.21) 0.64 (0.19) −0.114 (0.632) −0.108 (0.739) −0.215 (0.503) 
Longest Step Time (s) 0.88 (0.24) 0.93 (0.23) 0.80 (0.26) 0.209 (0.376) −0.038 (0.906) 0.259 (0.417) 
Arrhythmicity (%) 11.6 (5.58) 11.3 (6.5) 12.2 (4.0) 0.264 (0.261) 0.118 (0.715) 0.350 (0.265) 
Average Stance Time (s) 0.65 (0.60) 0.61 (0.60) 0.72 (0.61) 0.258 (0.272) 0.108 (0.739) 0.348 (0.267) 
Longest Stance Time (s) 1.69 (2.39) 1.63 (2.75) 1.77 (1.77) −0.271 (0.247) 0.132 (0.682) −0.358 (0.253) 
3.2. Relation of SIP Parameters to Disease Severity and Postural Instability 
In total, two out of the eight parameters—knee amplitude and longest stance time—were 
correlated with clinical ratings MDS-UPDRS III, and another two (arrhythmicity and average stance 
time) showed a trend (p < 0.05). Specifically, knee amplitude was reduced in subjects with higher 
clinical ratings (MDS-UPDRS III rho = −0.507, p-value = 0.003), while longest stance time increased 
(rho = 0.523, p-value = 0.002). The correlations with pull test ratings of postural instability were in the 
same direction, but reached significance only for longest stance time (Table 4). Trends indicated an 
increase of arrhythmicity and average stance time with more severe clinical ratings. 
Table 4. Spearman’s rank correlation of the eight kinematic parameters with clinical ratings acquired 
at the time of each SIP recording; analyzed from the pooled dataset (n = 33). 
 Spear. Corr. MDS-UPDRS III Spear. Corr. Pull Test 
 Rho (p-Value) Rho (p-Value) 
Cadence (steps/min) −0.234 (0.189) −0.328 (0.072) 
Knee Amplitude (cm) −0.507 (0.003) −0.436 (0.014) * 
Asymmetry (%) 0.202 (0.260) 0.170 (0.361) 
Average Step Time (s) −0.287 (0.105) −0.274 (0.136) 
Longest Step Time (s) −0.291 (0.101) −0.242 (0.191) 
Arrhythmicity (%) 0.352 (0.045) * 0.452 (0.011) * 
Average Stance Time (s) 0.374 (0.032) * 0.374 (0.038) * 
Longest Stance Time (s) 0.523 (0.002) 0.468 (0.008) 
Statistically significant outcomes are set in bold; * indicates trend (p-value < 0.05). 
3.3. Comparison between Recordings Taken in ON vs. OFF States 
As expected, the clinical rating indicated relevant within-group change in motor symptoms from 
OFF to ON states (29% decrease in MDS-UPDRS III) in the subset with assessments available from 
both conditions. Changes in SIP behavior from OFF to ON were reflected in increase of knee 
amplitude (85.4%, p-value = 0.002) and average step time (14.5%, p-value = 0.007), a decrease of step 
asymmetry (−19.6%, p-value = 0.007) with a similar trend for arrhythmicity, while cadence remained 
unchanged (Table 5). On inspection of corresponding data plots, a consistent change between OFF 
and ON was only seen for knee amplitude, which closely reflected respective differences in MDS-
UPDRS III (Figure 4). The pronounced increase in longest stance time from OFF to ON, though non-
significant, was unexpected in direction. This parameter reflects hesitations in stepping that would 
be expected to become less with effective therapy. However, inspection of data revealed one very 
long FOG episode (>20 s) during one recording in ON condition with a relevant impact on parameter 
mean.  
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Table 5. Changes in SIP parameters and clinical rating from OFF to ON state in the subset with 
assessments in both conditions available (n = 10). 
 Mean (SD) OFF Mean (SD) ON Diff Abs. Diff [%] SRM Paired t-Test p-Value 
MDS-UPDRS III 37.2 (14.53) 28.8 (13.37) 10.64 −28.6 1.69 <0.001 
Cadence (steps/min) 96.6 (29.0) 96.9 (20.7) 0.36 0.4 −0.02 0.954 
Knee Amplitude (cm) 7.08 (4.0) 13.1 (6.2) 6.05 85.4 −1.34 0.002 
Asymmetry (%) 21.9 (27.6) 17.7 (18.3) −4.30 −19.6 0.14 0.007 
Average Step Time (s) 0.61 (0.17) 0.71 (0.14) 0.09 14.5 −1.09 0.007 
Longest Step Time (s) 0.76 (0.21) 0.81 (0.14) 0.05 7.2 −0.35 0.298 
Arrhythmicity (%) 11.9 (3.50) 8.46 (3.93) −3.49 −29.3 0.84 0.025 
Average Stance Time (s) 0.80 (0.67) 0.62 (0.51) −0.18 −23.0 0.55 0.114 
Longest Stance Time (s) 1.88 (1.87) 3.67 (8.04) 1.79 94.6 −0.27 0.423 
Statistically significant outcomes are set in bold. 
 
Figure 4. Changes of knee amplitude between treatment states (left) and knee amplitude changes 
related to disease severity change. 
3.4. Implications of FOG and Other Motor Patterns 
Freezing of stepping was clinically observed during 7 out of 33 recordings (ON: n = 6; OFF: n = 
1). Examples from our sample (Figure 5) illustrate possible effects of FOG behavior on SIP parameters. 
In contrast to normal stepping behavior with constant rhythm and amplitude (Figure 5 top), 
hesitations and slower movements would be expected to result in increase of longest and average 
stance time, step time, and, therefore, lower cadence (Figure 5, line two from top). Related to this 
movement behavior, arrhythmicity can be found as well, and may show remarkable asymmetry 
(lines two and three). Festination prior to freezing manifestation may result in decrease of average 
knee amplitude, step, and stance timing, with remarkable asymmetry (third example). The 
manifestation of freezing will clearly result in massive increases of longest stance time as the 
prominent and possibly defining feature (lines three and four), usually in company with reduced 
knee amplitude and increased arrhythmicity. 
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Figure 5. Illustration of freezing of gait (FOG) related changes on SIP behavior from our sample: 
normal rhythmic stepping behavior of regular and symmetric amplitude (top); hesitations of stepping 
with asymmetrical inconsistent stepping behavior and slowing of movements at the end (second from 
top); progressively ineffective stepping with small movement, asymmetry, and freezing of stepping 
at the end (third from top); ineffective highly irregular low-amplitude stepping and freezing of 
stepping in first half and at the end (bottom). 
4. Discussion 
Our study explored the instrumental assessment of motor signs in patients with Parkinson’s 
disease using SIP as a standard motor task performed in front of a single RGBD camera. Both 
technology and task were chosen for their potential application as patient-based assessment in the 
home setting, although recordings were done in the lab at this stage. 
The 3D motion signals of knees were used to derive eight different kinematic parameters for the 
description of stepping behavior in SIP. This extends previous SIP descriptions [23,24,28] to the 
spatial domain, including amplitude and spatial symmetry of stepping. Although foot signals from 
RGBD recordings have been used for step detection in normal gait [29,30], we preferred knee signals, 
because they showed less noise behavior compared to foot and ankle landmarks in an earlier 
validation of our system [21]. The kinematic parameters were selected to reflect key motor aspects of 
PD. Knee amplitude and step time are conceived to describe hypo/bradykinesia, similar to shortening 
of stepping during gait at self-selected speed, which can be considered the main gait characteristic in 
PWPD [31,32]. Temporal asymmetry is an important feature, specifically in the early stages of the 
disease [33,34], and reduced interlimb coordination has also been related to FOG [4,27]. Interestingly, 
spatial asymmetry of stepping during gait has been related to postural control [35] instead of 
temporal asymmetry, and might be specifically affected in subtypes of PWPD [36]. 
Changes in cadence were not consistently seen in previous gait descriptions in PWPD, but an 
increase of cadence and shorter step times in PWPD may indicate festination of stepping. In contrast, 
increasing stance times may indicate hesitations, and excessive longest stance times may indicate 
episodes of ineffective stepping or freezing. Variability of stepping, specifically step and stride timing 
during gait, forms a separate domain of gait as conceptualized by Lord et al., [32], which has gained 
increasing interest in the assessment of PWPD [16,37]. We therefore included arrhythmicity of 
stepping, similar to the coefficient of variance for step or stride time that is used as common 
descriptor in gait analysis, which is sensitive to number of steps, as well as the gait paradigm used 
for recording [38]. Although the similarity of SIP movement to stepping during gait is intriguing, we 
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are aware of only one small study [23] which compared cadence from SIP and gait recordings. Thus, 
our parameter wording should not imply that we consider specific parameters directly comparable 
to gait descriptions in PWPD. We therefore also refer to freezing of stepping in our observations, 
although it obviously shares features with FOG. 
Prior to this work, there were only a few publications on the instrumental assessments of SIP. In 
our study, stepping in place was instructed to evoke self-selected stepping pace without any external 
cueing. Differences in task instructions as well as sample characteristics may contribute to explain 
the slightly lower cadence reported here, compared to previous reports (97–99 steps/min in our study 
vs. 100–112 steps/min from [23,24,28]). Derived spatial asymmetry values presented in this work were 
notably higher than the reported temporal swing time asymmetry during SIP by Nantel et al. [24], 
which may indicate limitations in the comparability of spatial and temporal asymmetry measures. 
Comparability of measurements to age-matched healthy volunteers should be considered for future 
works, to define normal stepping behavior in this task and corroborate evidence on analogies and 
differences to stepping behavior during gait. Furthermore, although our results did not suggest 
dependency on age, body height, or weight, potential confounders need to be analyzed in more 
appropriate datasets, as well as variability of performance with repeated testing. For use in PWPD, 
this test series showed excellent applicability of RGBD-instrumented SIP, even in higher disease 
stages. Still, the need for well-standardized procedures of data acquisition and for quality control of 
acquired data, specifically in remote application, needs not be neglected to make this a useful aid to 
clinicians and disease management in PWPD. 
With respect to clinical validity, correlation analysis in our cohort indicated that smaller knee 
amplitude and longer stance times reflect higher disease severity. As knee amplitude can be 
conceived as the spatial parameter of stepping, this finding corresponds well to reduced step length 
during gait. While stance time during gait may increase with need to stabilize gait, often in parallel 
with reduction in gait speed, it has, to our knowledge, not been explored as an indicator of hesitations 
in stepping, nor has longest stance time been reported as an indicator of FOG episodes. Our 
observation of excessive longest stance time in individuals who experience freezing of stepping 
during SIP would support this concept. Future study may define useful thresholds for an automated 
detection of freezing and related behaviors, as exemplified in Figure 5. Both knee amplitude and 
longest stance time, but also arrhythmicity, showed substantial correlations to the clinical rating of 
postural instability from pull test performance. This is remarkable, as postural instability in PWPD is 
a motor feature of high clinical relevance regarding prognosis, fall risk, and interventions, yet hard 
to assess clinically. Pull test performance and rating notably suffers low reliability [39]. Therefore, 
future study should aim to corroborate this finding, which further supports the notion that SIP tests 
aspects of postural control, in addition to aspects of gait.  
From the 33 SIP recordings, seven included freezing episodes, according to operator 
observation, as well as inspection of knee signals. This supports the notion that the SIP task triggers 
freezing of stepping [24,25]. The occurrence of FOG is known to depend on environmental cues as 
well as the type of motor task, where increased task complexity and cognitive demands increase FOG 
appearance [40,41]. Previous reports indicating cognitive demand of SIP execution [28] could explain 
the appearance of freezing in this task. However, our study was not designed to further explore the 
diagnostic accuracy of SIP for FOG detections. This would need a study design that compares 
matched samples of freezers and non-freezers, defined along established standards and against more 
detailed clinical ratings of FOG and related phenomena. Other motor tasks, such as 360° turns or 
walking through doorways, might have a higher probability of triggering FOG [25]. Unfortunately, 
due to occlusion of body parts during execution, the extraction of reliable kinematic parameters from 
turn tasks proves difficult when using markerless motion capture technology.  
The comparison between ON and OFF recordings from a subgroup of 10 PWPD aimed to 
explore the sensitivity to effects of intervention. As expected, these were reflected in a decrease in 
MDS-UPDRS III from OFF to ON, which can be considered as clinically relevant, both with regard to 
absolute and relative change [42,43]. This overt change in clinical state, however, left cadence 
unchanged, while knee amplitude and average step time increased and spatial asymmetry decreased 
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(trend for decrease in arrhythmicity). Specifically, the average proportional increase of knee 
amplitude (85%) was much higher than the relative change observed in clinical ratings (−29%), 
suggestive of a higher sensitivity to change compared to clinical rating. This can, however, only be 
confirmed if retest reliability has been determined. Concerning average step time, the appearance of 
a very long FOG episode (>20 s) in one ON recording might have influenced statistical analysis of 
this parameter, and explains the massive increase in longest stance time for OFF to ON. 
The advantage of markerfree motion capture, in comparison to single or multiple wearable 
sensors, is the potential analysis of the full body. After consideration of required accuracy levels, 
signal analysis may extend to other body parts, and could be used to describe arm swing or torso 
sway dynamics during task performance. From clinical observation, such measures seem interesting 
candidates for a description of dyskinesia in PWPD. This was not considered in our study, as 
recordings with dyskinesia were deliberately excluded, but is clearly needed in further validation of 
this task for clinical application in PWPD.  
From this first kinematic analysis, SIP alone may capture a variety of clinically relevant PD motor 
symptoms within one test, including FOG, although the relation of SIP performance to hand 
functions and dyskinesia have not yet been investigated. The task could also be modified with respect 
to duration or by adding cognitive or motor dual task conditions. The literature shows that, in 
conventional gait tasks, adding further cognitive load via dual tasking increases FOG appearance 
and alters movement patterns in PWPD [8,44]. Whether this also holds true for SIP, as a non-
locomotor stepping task, still needs to be shown.  
5. Conclusions 
In this sample of 25 PWPD, all patients were able to perform the 40 s stepping in place task in 
OFF and ON therapeutic state. Freezing episodes were seen during some of the SIP performances in 
OFF as well as ON, confirming previous reports. From all recordings, a set of kinematic parameters 
were derived, describing range of movement (knee amplitude), arrhythmicity, and asymmetry, as 
well as stance timing. As an indicator of clinical validity, some parameters showed relations to clinical 
ratings of disease severity, specifically postural instability. Measures of knee amplitude showed also 
consistent changes between OFF and ON states, indicating high responsiveness of this parameter. 
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